One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.
N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.
N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.
N-of-One has launched a new service called PrecisionInsights through which it will provide clinical interpretation for small, targeted gene panels.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
N-of-One will provide clinical interpretation for GenomiCare's next-generation sequencing-based tumor exome profiling test in China.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.